Connection

CURTIS A PETTAWAY to Prostatic Neoplasms

This is a "connection" page, showing publications CURTIS A PETTAWAY has written about Prostatic Neoplasms.
Connection Strength

5.321
  1. Germline Mutations in African American Men With Prostate Cancer: Incidence, Implications and Diagnostic Disparities. Urology. 2022 05; 163:148-155.
    View in: PubMed
    Score: 0.244
  2. Germline Predisposition to Prostate Cancer in Diverse Populations. Urol Clin North Am. 2021 Aug; 48(3):411-423.
    View in: PubMed
    Score: 0.241
  3. African American and Asian males: what do we know about germline predisposition to prostate cancer. Can J Urol. 2019 Oct; 26(5 Suppl 2):27-28.
    View in: PubMed
    Score: 0.214
  4. Benign prostatic hyperplasia: racial differences in treatment patterns and prostate cancer prevalence. BJU Int. 2011 Oct; 108(8):1302-8.
    View in: PubMed
    Score: 0.118
  5. Long-term quality of life after radical prostatectomy in wives of men in the postoperative adjuvant androgen deprivation trial. Support Care Cancer. 2011 Aug; 19(8):1117-24.
    View in: PubMed
    Score: 0.112
  6. Downmodulation of Bcl-2 sensitizes metastatic LNCaP-LN3 cells to undergo apoptosis via the intrinsic pathway. Prostate. 2010 May 01; 70(6):571-83.
    View in: PubMed
    Score: 0.111
  7. Neoadjuvant platelet derived growth factor receptor inhibitor therapy combined with docetaxel and androgen ablation for high risk localized prostate cancer. J Urol. 2009 Jan; 181(1):81-7; discussion 87.
    View in: PubMed
    Score: 0.101
  8. The ratio of matrix metalloproteinase to E-cadherin expression: a pilot study to assess mRNA and protein expression among African American prostate cancer patients. Prostate. 2008 Sep 15; 68(13):1467-76.
    View in: PubMed
    Score: 0.099
  9. A randomized prospective trial evaluating testosterone, haemoglobin kinetics and quality of life, during and after 12 months of androgen deprivation after prostatectomy: results from the Postoperative Adjuvant Androgen Deprivation trial. BJU Int. 2007 Jul; 100(1):63-9.
    View in: PubMed
    Score: 0.091
  10. Knowledge of hereditary prostate cancer among high-risk African American men. Oncol Nurs Forum. 2007 Jul; 34(4):854-60.
    View in: PubMed
    Score: 0.091
  11. African-American men with nonpalpable prostate cancer exhibit greater tumor volume than matched white men. Cancer. 2006 Jul 01; 107(1):75-82.
    View in: PubMed
    Score: 0.085
  12. Expression of interleukin-8 gene in radical prostatectomy specimens is associated with advanced pathologic stage. Prostate. 2005 Jun 15; 64(1):40-9.
    View in: PubMed
    Score: 0.079
  13. Enhanced invasion of hormone refractory prostate cancer cells through hepatocyte growth factor (HGF) induction of urokinase-type plasminogen activator (u-PA). Prostate. 2004 May 01; 59(2):167-76.
    View in: PubMed
    Score: 0.073
  14. The association of body mass index with tumor aggression among men undergoing radical prostatectomy. Urol Oncol. 2024 04; 42(4):116.e1-116.e7.
    View in: PubMed
    Score: 0.072
  15. The relative mRNA expression levels of matrix metalloproteinase to E-cadherin in prostate biopsy specimens distinguishes organ-confined from advanced prostate cancer at radical prostatectomy. Clin Cancer Res. 2003 Jun; 9(6):2185-94.
    View in: PubMed
    Score: 0.069
  16. Immune and pathologic responses in patients with localized prostate cancer who received daratumumab (anti-CD38) or edicotinib (CSF-1R inhibitor). J Immunother Cancer. 2023 03; 11(3).
    View in: PubMed
    Score: 0.068
  17. Deconstructing, Addressing, and Eliminating Racial and Ethnic Inequities in Prostate Cancer Care. Eur Urol. 2022 10; 82(4):341-351.
    View in: PubMed
    Score: 0.064
  18. Epigenome-Wide Association Study of Prostate Cancer in African Americans Identifies DNA Methylation Biomarkers for Aggressive Disease. Biomolecules. 2021 12 03; 11(12).
    View in: PubMed
    Score: 0.062
  19. Study protocol: One plus one can be greater than two-Ecological momentary assessment for Black prostate cancer survivors and partners. PLoS One. 2021; 16(8):e0255614.
    View in: PubMed
    Score: 0.061
  20. Active Surveillance for Black Men With Low-Risk Prostate Cancer. JAMA. 2020 11 03; 324(17):1733-1734.
    View in: PubMed
    Score: 0.058
  21. Cultural Adaptation of Evidence-Based Lifestyle Interventions for African American Men With Prostate Cancer: A Dyadic Approach. Am J Mens Health. 2020 Nov-Dec; 14(6):1557988320945449.
    View in: PubMed
    Score: 0.058
  22. Leukocyte telomere length is associated with aggressive prostate cancer in localized African American prostate cancer patients. Carcinogenesis. 2020 09 24; 41(9):1213-1218.
    View in: PubMed
    Score: 0.057
  23. Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019. J Clin Oncol. 2020 08 20; 38(24):2798-2811.
    View in: PubMed
    Score: 0.056
  24. Relative expression of type IV collagenase, E-cadherin, and vascular endothelial growth factor/vascular permeability factor in prostatectomy specimens distinguishes organ-confined from pathologically advanced prostate cancers. Clin Cancer Res. 2000 Jun; 6(6):2295-308.
    View in: PubMed
    Score: 0.056
  25. Neoadjuvant chemotherapy and hormonal therapy followed by radical prostatectomy: feasibility and preliminary results. J Clin Oncol. 2000 Mar; 18(5):1050-7.
    View in: PubMed
    Score: 0.055
  26. Determining Clinically Based Factors Associated With Reclassification in the Pre-MRI Era using a Large Prospective Active Surveillance Cohort. Urology. 2020 04; 138:91-97.
    View in: PubMed
    Score: 0.054
  27. Racial differences in the androgen/androgen receptor pathway in prostate cancer. J Natl Med Assoc. 1999 Dec; 91(12):653-60.
    View in: PubMed
    Score: 0.054
  28. Contemporary prostate cancer treatment choices in multidisciplinary clinics referenced to national trends. Cancer. 2020 02 01; 126(3):506-514.
    View in: PubMed
    Score: 0.054
  29. Comparative analysis of p16 expression among African American and European American prostate cancer patients. Prostate. 2019 08; 79(11):1274-1283.
    View in: PubMed
    Score: 0.052
  30. Prostate cancer in African-American men: outcome following radiation therapy with or without adjuvant androgen ablation. Int J Radiat Oncol Biol Phys. 1998 Oct 01; 42(3):517-23.
    View in: PubMed
    Score: 0.050
  31. Prostate specific antigen and pathological features of prostate cancer in black and white patients: a comparative study based on radical prostatectomy specimens. J Urol. 1998 Aug; 160(2):437-42.
    View in: PubMed
    Score: 0.049
  32. Cost and efficacy comparison of five prostate biopsy modalities: a platform for integrating cost into novel-platform comparative research. Prostate Cancer Prostatic Dis. 2018 11; 21(4):524-532.
    View in: PubMed
    Score: 0.049
  33. Prognostic markers in clinically localized prostate cancer. Tech Urol. 1998 Mar; 4(1):35-42.
    View in: PubMed
    Score: 0.048
  34. Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017. J Clin Oncol. 2018 02 01; 36(4):414-424.
    View in: PubMed
    Score: 0.047
  35. Quality of life after brachytherapy or bilateral nerve-sparing robot-assisted radical prostatectomy for prostate cancer: a prospective cohort. BJU Int. 2018 04; 121(4):540-548.
    View in: PubMed
    Score: 0.047
  36. Baseline and longitudinal plasma caveolin-1 level as a biomarker in active surveillance for early-stage prostate cancer. BJU Int. 2018 01; 121(1):69-76.
    View in: PubMed
    Score: 0.046
  37. Genetic ancestry and prostate cancer susceptibility SNPs in Puerto Rican and African American men. Prostate. 2017 Jul; 77(10):1118-1127.
    View in: PubMed
    Score: 0.045
  38. Is active surveillance a suitable option for African American men with prostate cancer? A systemic literature review. Prostate Cancer Prostatic Dis. 2017 06; 20(2):127-136.
    View in: PubMed
    Score: 0.045
  39. VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer. Nat Med. 2017 May; 23(5):551-555.
    View in: PubMed
    Score: 0.045
  40. Transformation of prostatic adenocarcinoma to well-differentiated neuroendocrine tumor after hormonal treatment. Hum Pathol. 2017 06; 64:186-190.
    View in: PubMed
    Score: 0.044
  41. Impact of ethnicity on the outcome of men with metastatic, hormone-sensitive prostate cancer. Cancer. 2017 May 01; 123(9):1536-1544.
    View in: PubMed
    Score: 0.044
  42. Apoptosis resistance increases with metastatic potential in cells of the human LNCaP prostate carcinoma line. Cancer Res. 1996 Dec 15; 56(24):5594-9.
    View in: PubMed
    Score: 0.044
  43. Informed decision making before prostate-specific antigen screening: Initial results using the American Cancer Society (ACS) Decision Aid (DA) among medically underserved men. Cancer. 2017 02 15; 123(4):583-591.
    View in: PubMed
    Score: 0.044
  44. Selection of highly metastatic variants of different human prostatic carcinomas using orthotopic implantation in nude mice. Clin Cancer Res. 1996 Sep; 2(9):1627-36.
    View in: PubMed
    Score: 0.043
  45. Adenoid cystic carcinoma of the urethra/Cowper's gland with concurrent high-grade prostatic adenocarcinoma: a detailed clinicopathologic case report and review of the literature. Hum Pathol. 2016 12; 58:138-144.
    View in: PubMed
    Score: 0.043
  46. An Approach Using PSA Levels of 1.5?ng/mL as the Cutoff for Prostate Cancer Screening in Primary Care. Urology. 2016 Oct; 96:116-120.
    View in: PubMed
    Score: 0.043
  47. Robotic-assisted laparoscopic versus open salvage radical prostatectomy following radiotherapy. Can J Urol. 2016 Jun; 23(3):8271-7.
    View in: PubMed
    Score: 0.042
  48. CXCL1 mediates obesity-associated adipose stromal cell trafficking and function in the tumour microenvironment. Nat Commun. 2016 05 31; 7:11674.
    View in: PubMed
    Score: 0.042
  49. Atlas of prostate cancer heritability in European and African-American men pinpoints tissue-specific regulation. Nat Commun. 2016 Apr 07; 7:10979.
    View in: PubMed
    Score: 0.042
  50. Tissue Effects in a Randomized Controlled Trial of Short-term Finasteride in Early Prostate Cancer. EBioMedicine. 2016 May; 7:85-93.
    View in: PubMed
    Score: 0.042
  51. Prostate Cancer Susceptibility in Men of African Ancestry at 8q24. J Natl Cancer Inst. 2016 Jul; 108(7).
    View in: PubMed
    Score: 0.041
  52. Neoadjuvant Systemic Therapy Before Radical Prostatectomy in High-Risk Prostate Cancer Does Not Increase Surgical Morbidity: Contemporary Results Using the Clavien System. Clin Genitourin Cancer. 2016 Apr; 14(2):130-8.
    View in: PubMed
    Score: 0.041
  53. A randomized, double-blind, placebo-controlled study of the effects of pomegranate extract on rising PSA levels in men following primary therapy for prostate cancer. Prostate Cancer Prostatic Dis. 2015 Sep; 18(3):242-8.
    View in: PubMed
    Score: 0.040
  54. Integration of multiethnic fine-mapping and genomic annotation to prioritize candidate functional SNPs at prostate cancer susceptibility regions. Hum Mol Genet. 2015 Oct 01; 24(19):5603-18.
    View in: PubMed
    Score: 0.040
  55. Disease reclassification risk with stringent criteria and frequent monitoring in men with favourable-risk prostate cancer undergoing active surveillance. BJU Int. 2016 07; 118(1):68-76.
    View in: PubMed
    Score: 0.040
  56. Integrating chemohormonal therapy and surgery in known or suspected lymph node metastatic prostate cancer. Prostate Cancer Prostatic Dis. 2015 Sep; 18(3):276-80.
    View in: PubMed
    Score: 0.040
  57. Robotic or open radical prostatectomy after previous open surgery in the pelvic region. Korean J Urol. 2015 Feb; 56(2):131-7.
    View in: PubMed
    Score: 0.039
  58. A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer. Nat Genet. 2014 Oct; 46(10):1103-9.
    View in: PubMed
    Score: 0.038
  59. Generalizability of established prostate cancer risk variants in men of African ancestry. Int J Cancer. 2015 Mar 01; 136(5):1210-7.
    View in: PubMed
    Score: 0.037
  60. Impact of a clinical trial initiative on clinical trial enrollment in a multidisciplinary prostate cancer clinic. J Natl Compr Canc Netw. 2014 Jul; 12(7):993-8.
    View in: PubMed
    Score: 0.037
  61. Local recurrence map to guide target volume delineation after radical prostatectomy. Pract Radiat Oncol. 2014 Nov-Dec; 4(6):e239-46.
    View in: PubMed
    Score: 0.037
  62. Treatment decisions for localized prostate cancer: a concept mapping approach. Health Expect. 2015 Dec; 18(6):2079-90.
    View in: PubMed
    Score: 0.036
  63. Treatment regret and quality of life following radical prostatectomy. Support Care Cancer. 2013 Dec; 21(12):3337-43.
    View in: PubMed
    Score: 0.035
  64. Prostate cancer incidence and mortality among Puerto Ricans: an updated analysis comparing men in Puerto Rico with US racial/ethnic groups. P R Health Sci J. 2012 Sep; 31(3):107-13.
    View in: PubMed
    Score: 0.033
  65. Integrated Hedgehog signaling is induced following castration in human and murine prostate cancers. Prostate. 2013 Jan; 73(2):153-61.
    View in: PubMed
    Score: 0.032
  66. Comparative effectiveness, cost, and utilization of radical prostatectomy among young men within managed care insurance plans. Value Health. 2012 Mar-Apr; 15(2):367-75.
    View in: PubMed
    Score: 0.031
  67. Prostate-specific antigen 1.5-4.0 ng/mL: a diagnostic challenge and danger zone. BJU Int. 2011 Dec; 108(11):1743-9.
    View in: PubMed
    Score: 0.030
  68. Usefulness of prostate-specific antigen (PSA) rise as a marker of prostate cancer in men treated with dutasteride: lessons from the REDUCE study. BJU Int. 2012 Apr; 109(8):1162-9.
    View in: PubMed
    Score: 0.030
  69. Persistent, biologically meaningful prostate cancer after 1 year of androgen ablation and docetaxel treatment. J Clin Oncol. 2011 Jun 20; 29(18):2574-81.
    View in: PubMed
    Score: 0.030
  70. Increasing low risk prostate cancer incidence in United States Air Force servicemen and selection of treatments. J Urol. 2011 Jun; 185(6):2137-42.
    View in: PubMed
    Score: 0.030
  71. Presurgical stress management improves postoperative immune function in men with prostate cancer undergoing radical prostatectomy. Psychosom Med. 2011 Apr; 73(3):218-25.
    View in: PubMed
    Score: 0.029
  72. The effect of dutasteride on the usefulness of prostate specific antigen for the diagnosis of high grade and clinically relevant prostate cancer in men with a previous negative biopsy: results from the REDUCE study. J Urol. 2011 Jan; 185(1):126-31.
    View in: PubMed
    Score: 0.029
  73. Prioritizing genes associated with prostate cancer development. BMC Cancer. 2010 Nov 02; 10:599.
    View in: PubMed
    Score: 0.029
  74. Effect of dutasteride on the risk of prostate cancer. N Engl J Med. 2010 Apr 01; 362(13):1192-202.
    View in: PubMed
    Score: 0.028
  75. Morphologic characterization of preoperatively treated prostate cancer: toward a post-therapy histologic classification. Eur Urol. 2010 Jun; 57(6):1030-8.
    View in: PubMed
    Score: 0.027
  76. The effects of a presurgical stress management intervention for men with prostate cancer undergoing radical prostatectomy. J Clin Oncol. 2009 Jul 01; 27(19):3169-76.
    View in: PubMed
    Score: 0.026
  77. Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst. 2009 Mar 04; 101(5):306-20.
    View in: PubMed
    Score: 0.026
  78. Anti-CTLA-4 therapy results in higher CD4+ICOShi T cell frequency and IFN-gamma levels in both nonmalignant and malignant prostate tissues. Proc Natl Acad Sci U S A. 2009 Feb 24; 106(8):2729-34.
    View in: PubMed
    Score: 0.026
  79. Association of HPC2/ELAC2 and RNASEL non-synonymous variants with prostate cancer risk in African American familial and sporadic cases. Prostate. 2008 Dec 01; 68(16):1790-7.
    View in: PubMed
    Score: 0.025
  80. Randomized phase II trial evaluation of erectile function after attempted unilateral cavernous nerve-sparing retropubic radical prostatectomy with versus without unilateral sural nerve grafting for clinically localized prostate cancer. Eur Urol. 2009 May; 55(5):1135-43.
    View in: PubMed
    Score: 0.025
  81. Saturated fat intake predicts biochemical failure after prostatectomy. Int J Cancer. 2008 Jun 01; 122(11):2581-5.
    View in: PubMed
    Score: 0.024
  82. Prostate cancer in Mexican-Americans: identification of risk factors. Prostate. 2008 Apr 01; 68(5):563-70.
    View in: PubMed
    Score: 0.024
  83. Treatment outcomes of small cell carcinoma of the prostate: a single-center study. Cancer. 2007 Oct 15; 110(8):1729-37.
    View in: PubMed
    Score: 0.023
  84. Salvage prostatectomy with bladder neck closure, continent catheterizable stoma and bladder augmentation: feasibility and patient reported continence outcomes at 32 months. J Urol. 2007 Jun; 177(6):2200-4; discussion 2204.
    View in: PubMed
    Score: 0.023
  85. Initial modulation of the tumor microenvironment accounts for thalidomide activity in prostate cancer. Clin Cancer Res. 2007 Feb 15; 13(4):1224-31.
    View in: PubMed
    Score: 0.022
  86. Moderator analyses of participants in the Active for Life after cancer trial: implications for physical activity group intervention studies. Ann Behav Med. 2007 Feb; 33(1):99-104.
    View in: PubMed
    Score: 0.022
  87. Prostate cancer progression in the presence of undetectable or low serum prostate-specific antigen level. Cancer. 2007 Jan 15; 109(2):198-204.
    View in: PubMed
    Score: 0.022
  88. Genome-wide linkage of 77 families from the African American Hereditary Prostate Cancer study (AAHPC). Prostate. 2007 Jan 01; 67(1):22-31.
    View in: PubMed
    Score: 0.022
  89. Active for Life After Cancer: a randomized trial examining a lifestyle physical activity program for prostate cancer patients. Psychooncology. 2006 Oct; 15(10):847-62.
    View in: PubMed
    Score: 0.022
  90. Prostate cancer screening and detection in inner-city and underserved men. J Natl Med Assoc. 2006 Apr; 98(4):515-9.
    View in: PubMed
    Score: 0.021
  91. Cystoprostatectomy for effective palliation of symptomatic bladder invasion by prostate cancer. J Urol. 2005 Dec; 174(6):2186-90.
    View in: PubMed
    Score: 0.020
  92. Obesity, weight gain, and risk of biochemical failure among prostate cancer patients following prostatectomy. Clin Cancer Res. 2005 Oct 01; 11(19 Pt 1):6889-94.
    View in: PubMed
    Score: 0.020
  93. A common nonsense mutation in EphB2 is associated with prostate cancer risk in African American men with a positive family history. J Med Genet. 2006 Jun; 43(6):507-11.
    View in: PubMed
    Score: 0.020
  94. Changes in serum proteomic patterns by presurgical alpha-tocopherol and L-selenomethionine supplementation in prostate cancer. Cancer Epidemiol Biomarkers Prev. 2005 Jul; 14(7):1697-702.
    View in: PubMed
    Score: 0.020
  95. Blockade of transforming growth factor-beta signaling suppresses progression of androgen-independent human prostate cancer in nude mice. Clin Cancer Res. 2005 Jun 15; 11(12):4512-20.
    View in: PubMed
    Score: 0.020
  96. Transrectal ultrasound versus magnetic resonance imaging for detection of rectal wall invasion by prostate cancer. Prostate. 2005 Jan 01; 62(1):101-4.
    View in: PubMed
    Score: 0.019
  97. Prognostic factors for survival among Caucasian, African-American and Hispanic men with androgen-independent prostate cancer. J Natl Med Assoc. 2004 Dec; 96(12):1587-93.
    View in: PubMed
    Score: 0.019
  98. Androgen receptor polymorphisms and risk of biochemical failure among prostatectomy patients. Prostate. 2004 Sep 01; 60(4):343-51.
    View in: PubMed
    Score: 0.019
  99. Racial influence on biochemical disease-free survival in men treated with external-beam radiotherapy for localized prostate cancer. J Natl Med Assoc. 2004 Jul; 96(7):939-44.
    View in: PubMed
    Score: 0.019
  100. Potent antitumor activity after systemic delivery of a doubly fusogenic oncolytic herpes simplex virus against metastatic prostate cancer. Prostate. 2004 Jun 15; 60(1):53-60.
    View in: PubMed
    Score: 0.019
  101. Quality of life intervention for prostate cancer patients: design and baseline characteristics of the active for life after cancer trial. Control Clin Trials. 2004 Jun; 25(3):265-85.
    View in: PubMed
    Score: 0.018
  102. Evidence that transfer of functional p53 protein results in increased apoptosis in prostate cancer. Clin Cancer Res. 2004 Apr 15; 10(8):2587-93.
    View in: PubMed
    Score: 0.018
  103. Activator protein 2alpha inhibits tumorigenicity and represses vascular endothelial growth factor transcription in prostate cancer cells. Cancer Res. 2004 Jan 15; 64(2):631-8.
    View in: PubMed
    Score: 0.018
  104. Clinical characteristics of African-American men with hereditary prostate cancer: the AAHPC Study. Prostate Cancer Prostatic Dis. 2004; 7(2):165-9.
    View in: PubMed
    Score: 0.018
  105. Clinical features and treatment outcome of Hispanic men with prostate cancer following external beam radiotherapy. J Urol. 2003 Nov; 170(5):1856-9.
    View in: PubMed
    Score: 0.018
  106. Total pelvic exenteration: effective palliation of perineal pain in patients with locally recurrent prostate cancer. J Urol. 2003 Nov; 170(5):1868-71.
    View in: PubMed
    Score: 0.018
  107. Differential effects of the proteasome inhibitor bortezomib on apoptosis and angiogenesis in human prostate tumor xenografts. Mol Cancer Ther. 2003 Sep; 2(9):835-43.
    View in: PubMed
    Score: 0.018
  108. Anti-vascular endothelial growth factor receptor 2 antibody reduces tumorigenicity and metastasis in orthotopic prostate cancer xenografts via induction of endothelial cell apoptosis and reduction of endothelial cell matrix metalloproteinase type 9 production. Clin Cancer Res. 2002 Aug; 8(8):2714-24.
    View in: PubMed
    Score: 0.016
  109. Prostate carcinoma with testicular or penile metastases. Clinical, pathologic, and immunohistochemical features. Cancer. 2002 May 15; 94(10):2610-7.
    View in: PubMed
    Score: 0.016
  110. Inhibition of angiogenesis by the antiepidermal growth factor receptor antibody ImClone C225 in androgen-independent prostate cancer growing orthotopically in nude mice. Clin Cancer Res. 2002 May; 8(5):1253-64.
    View in: PubMed
    Score: 0.016
  111. African-American heredity prostate cancer study: a model for genetic research. J Natl Med Assoc. 2001 Dec; 93(12 Suppl):25S-28S.
    View in: PubMed
    Score: 0.016
  112. Interferon-alpha prevents selection of doxorubicin-resistant undifferentiated-androgen-insensitive metastatic human prostate cancer cells. Prostate. 2001 Sep 15; 49(1):19-29.
    View in: PubMed
    Score: 0.015
  113. Blockade of NF-kappaB activity in human prostate cancer cells is associated with suppression of angiogenesis, invasion, and metastasis. Oncogene. 2001 Jul 12; 20(31):4188-97.
    View in: PubMed
    Score: 0.015
  114. Genetic abnormalities specifically associated with varying metastatic potential of prostate cancer cell lines as detected by comparative genomic hybridization. Cancer Genet Cytogenet. 2001 Jun; 127(2):161-7.
    View in: PubMed
    Score: 0.015
  115. African-American heredity prostate cancer study: a model for genetic research. J Natl Med Assoc. 2001 Apr; 93(4):120-3.
    View in: PubMed
    Score: 0.015
  116. Incidental Detection of Urothelial Carcinoma on 18F-Fluciclovine PET/CT. Clin Nucl Med. 2021 Feb 01; 46(2):e114-e115.
    View in: PubMed
    Score: 0.015
  117. Recruitment experience in the first phase of the African American Hereditary Prostate Cancer (AAHPC) study. Ann Epidemiol. 2000 Nov; 10(8 Suppl):S68-77.
    View in: PubMed
    Score: 0.014
  118. Interleukin 8 expression regulates tumorigenicity and metastases in androgen-independent prostate cancer. Clin Cancer Res. 2000 May; 6(5):2104-19.
    View in: PubMed
    Score: 0.014
  119. Highly metastatic human prostate cancer growing within the prostate of athymic mice overexpresses vascular endothelial growth factor. Clin Cancer Res. 1999 Apr; 5(4):783-9.
    View in: PubMed
    Score: 0.013
  120. Suppression of angiogenesis, tumorigenicity, and metastasis by human prostate cancer cells engineered to produce interferon-beta. Cancer Res. 1999 Feb 15; 59(4):872-9.
    View in: PubMed
    Score: 0.013
  121. A feasibility study of cryotherapy followed by radical prostatectomy for locally advanced prostate cancer. J Urol. 1999 Feb; 161(2):509-14.
    View in: PubMed
    Score: 0.013
  122. Correlation of metastasis-related gene expression with metastatic potential in human prostate carcinoma cells implanted in nude mice using an in situ messenger RNA hybridization technique. Am J Pathol. 1997 May; 150(5):1571-82.
    View in: PubMed
    Score: 0.011
  123. The efficacy and complications of salvage cryotherapy of the prostate. J Urol. 1997 Mar; 157(3):921-5.
    View in: PubMed
    Score: 0.011
  124. Initial experience of teaching robot-assisted radical prostatectomy to surgeons-in-training: can training be evaluated and standardized? BJU Int. 2010 Apr; 105(8):1148-54.
    View in: PubMed
    Score: 0.007
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.